1
|
Pabois A, Bodo V, Boisson A, Crosignani S, De Henau O, Detheux M, Garaud S, Lager J, Martinoli C, Mercier M, Naveaux C, Thomas N, Wald N, Vezzu A, Willard-Gallo K, Houthuys E. Multiplex IHC panel development for adenosine pathway markers and TIL in human cancer specimens. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz452.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
2
|
Buisseret L, Pommey S, Allard B, Garaud S, Bergeron M, Cousineau I, Ameye L, Bareche Y, Paesmans M, Crown JPA, Di Leo A, Loi S, Piccart-Gebhart M, Willard-Gallo K, Sotiriou C, Stagg J. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial. Ann Oncol 2019; 29:1056-1062. [PMID: 29145561 DOI: 10.1093/annonc/mdx730] [Citation(s) in RCA: 121] [Impact Index Per Article: 24.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Background CD73 is an ecto-enzyme that promotes tumor immune escape through the production of immunosuppressive extracellular adenosine in the tumor microenvironment. Several CD73 inhibitors and adenosine receptor antagonists are being evaluated in phase I clinical trials. Patients and methods Full-face sections from formalin-fixed paraffin-embedded primary breast tumors from 122 samples of triple-negative breast cancer (TNBC) from the BIG 02-98 adjuvant phase III clinical trial were included in our analysis. Using multiplex immunofluorescence and image analysis, we assessed CD73 protein expression on tumor cells, tumor-infiltrating leukocytes and stromal cells. We investigated the associations between CD73 protein expression with disease-free survival (DFS), overall survival (OS) and the extent of tumor immune infiltration. Results Our results demonstrated that high levels of CD73 expression on epithelial tumor cells were significantly associated with reduced DFS, OS and negatively correlated with tumor immune infiltration (Spearman's R= -0.50, P < 0.0001). Patients with high levels of CD73 and low levels of tumor-infiltrating leukocytes had the worse clinical outcome. Conclusions Taken together, our study provides further support that CD73 expression is associated with a poor prognosis and reduced anti-tumor immunity in human TNBC and that targeting CD73 could be a promising strategy to reprogram the tumor microenvironment in this BC subtype.
Collapse
Affiliation(s)
- L Buisseret
- Research Centre, University of Montreal Hospital, Montréal, Canada; Montreal Cancer Institute, Montréal, Canada; Faculty of Pharmacy, Université de Montréal, Montréal, Canada; Molecular Immunology Unit, Brussels, Belgium; Breast Cancer Translational Research Laboratory J-C Heuson, Brussels, Belgium
| | - S Pommey
- Research Centre, University of Montreal Hospital, Montréal, Canada; Montreal Cancer Institute, Montréal, Canada; Faculty of Pharmacy, Université de Montréal, Montréal, Canada
| | - B Allard
- Research Centre, University of Montreal Hospital, Montréal, Canada; Montreal Cancer Institute, Montréal, Canada; Faculty of Pharmacy, Université de Montréal, Montréal, Canada
| | - S Garaud
- Molecular Immunology Unit, Brussels, Belgium
| | - M Bergeron
- Research Centre, University of Montreal Hospital, Montréal, Canada; Montreal Cancer Institute, Montréal, Canada; Faculty of Pharmacy, Université de Montréal, Montréal, Canada
| | - I Cousineau
- Research Centre, University of Montreal Hospital, Montréal, Canada; Montreal Cancer Institute, Montréal, Canada; Faculty of Pharmacy, Université de Montréal, Montréal, Canada
| | - L Ameye
- Data Centre, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - Y Bareche
- Breast Cancer Translational Research Laboratory J-C Heuson, Brussels, Belgium
| | - M Paesmans
- Data Centre, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - J P A Crown
- Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - A Di Leo
- Medical Oncology Department, Hospital of Prato, Prato, Italy
| | - S Loi
- Division of Clinical Medicine and Research, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - M Piccart-Gebhart
- Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | | | - C Sotiriou
- Breast Cancer Translational Research Laboratory J-C Heuson, Brussels, Belgium
| | - J Stagg
- Research Centre, University of Montreal Hospital, Montréal, Canada; Montreal Cancer Institute, Montréal, Canada; Faculty of Pharmacy, Université de Montréal, Montréal, Canada.
| |
Collapse
|
3
|
De Silva P, Stamatopoulos B, Chi V, Garaud S, Francois R, Thibaud V, Solinas C, Boisson A, Duvillier H, Rouas R, Lewalle P, Gallo K, Bron D. BACH2 AND FOXP1 GENE EXPRESSIONS ARE SIGNIFICANTLY ALTERED IN T AND B CELLS FROM CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS COMPARED TO AGED-MATCHED HEALTHY DONORS IMPACTING SURVIVAL. J Geriatr Oncol 2019. [DOI: 10.1016/s1879-4068(19)31173-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
4
|
De Silva P, Stamatopoulos B, Dang Chi V, Garaud S, Francois R, Thibaud V, Solinas C, Boisson A, Duvillier H, Rouas R, Lewalle P, Willard-Gallo K, Bron D. FOXP1, PD-1 AND PD-L1 ARE SIGNIFICANTLY UPREGULATED IN LYMPHOCYTES FROM CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS COMPARED TO AGE-MATCHED HEALTHY DONORS. Hematol Oncol 2019. [DOI: 10.1002/hon.46_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- P. De Silva
- Hematology; Institut Jules Bordet, ULB; Brussels Belgium
| | | | - V. Dang Chi
- Hematology; Institut Jules Bordet, ULB; Brussels Belgium
| | - S. Garaud
- Molecular Immunology Unit; Institut Jules Bordet, ULB; Brussels Belgium
| | - R. Francois
- Breast Cancer Translational Research Laboratory; Institut Jules Bordet, ULB; Brussels Belgium
| | - V. Thibaud
- Hematology; Institut Jules Bordet, ULB; Brussels Belgium
| | - C. Solinas
- Molecular Immunology Unit; Institut Jules Bordet, ULB; Brussels Belgium
| | - A. Boisson
- Molecular Immunology Unit; Institut Jules Bordet, ULB; Brussels Belgium
| | - H. Duvillier
- Flow Cytometry Core Facility; Institut Jules Bordet, ULB; Brussels Belgium
| | - R. Rouas
- Hematology; Institut Jules Bordet, ULB; Brussels Belgium
| | - P. Lewalle
- Hematology; Institut Jules Bordet, ULB; Brussels Belgium
| | - K. Willard-Gallo
- Molecular Immunology Unit; Institut Jules Bordet, ULB; Brussels Belgium
| | - D. Bron
- Hematology; Institut Jules Bordet, ULB; Brussels Belgium
| |
Collapse
|
5
|
Langouo Fontsa M, Noel G, Garaud S, de Wind A, Van den Eynden G, Boisson A, Naveaux C, Larsimont D, Piccart M, Willard-Gallo K. Immune functions of follicular helper CD4+CXCR5+ T cells in human breast cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz099.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
6
|
Szekely B, Bareche Y, Van den Eynden G, Salgado R, Buisseret L, Garaud S, Willard-Gallo K, Hatzis C, Szasz M, Kulka J, Larsimont D, Sotiriou C, Pusztai L, Desmedt C. Abstract PD5-10: Immune characterization of matched primary and multiple metastatic samples issued from an institutional autopsy cohort. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd5-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
While immune infiltrates have already been extensively characterized in primary tumors (P), data on breast cancer metastases (M) remains limited. To this end we quantified and qualified the immune cells in a unique cohort of multiple matched P and M samples selected from an institutional breast cancer autopsy cohort.
Patients and methods
Twenty-three patients were selected from an institutional autopsy program (Semmelweis University, Budapest, Hungary) based on matched P and M sample availability (124 samples). All samples were centrally characterized for estrogen (ER), progesterone (PR) and HER2 receptors. The primary molecular subtypes were as follows: 9 ER+/PR+/HER2-, 8 triple negative and 6 HER2+. Ten patients relapsed ≤1 year after diagnosis and were further referred to as “early relapsers”, as opposed to the remaining qualified as “late relapsers”. Immunohistochemistry (IHC) was carried out against CD3/CD20 and CD4/CD8 in 21 patients (119 samples). Tumor infiltrating lymphocytes (TILs) were assessed on hematoxylin and eosin (H&E) and CD3-stained slides. Gene expression data were generated using the NanoString nCounter assay (PanCancer Immune Profiling Panel) for 11 patients (35 samples) and analyzedusing the R package NanoStringQCPro. The scores from published immune gene signatures were calculated as a weighted sum of the expressions of their genes. All samples were analyzed for 22 immune cell subtypes relative abundance using CIBERSORT.
Results
TILs assessed on H&E and CD3-stained slides were weakly correlated (Rho= 0.38, p<.001). TIL levels as well as the number of tertiary lymphoid structures (TLS) were significantly lower in Ms as compared to Ps (p<.001). Among the different metastatic sites, the lung was more infiltrated when considering CD3+ and CD4+ cells (p=.01 and .02, respectively). We further observed significantly higher levels of TILs, CD3+, CD4+ and CD8+ cells in the Ms but not in the Ps from late relapsers as opposed to those from early relapsers. Gene expression analyses further confirmed these observations as several immune gene signatures displayed significantly higher scores in the Ms from late compared to early relapsers. An unsupervised analysis identified 13 genes significantly differentially expressed between Ps and Ms: CSF1R, CXCL14, CYBB, IL21R, IL2RB, TNF and TNFSF15 were upregulated in Ps while BCL2L1, C7, HSD11B1, and PSMB7 were upregulated in Ms. The matched P/M CIBERSORT analyses revealed a distinct composition of immune cell types between P and M of a same patient. Apart from a potential increase in M0 macrophages, no common trait was observed in immune cell composition between the Ms from the different patients.
Conclusion
This is to the best of our knowledge the first study characterizing the immune infiltration in patients with multiple matched P and M samples. The results suggest that Ms have not only a globally lower immune infiltration as compared to Ps, but also a different immune composition. Additionally, Ms from late relapsers are more infiltrated as compared to early relapsers. The present data also uncovers not only important inter-patient but also intra-patient immune heterogeneity, which should be taken into consideration for optimal treatment decision.
Citation Format: Szekely B, Bareche Y, Van den Eynden G, Salgado R, Buisseret L, Garaud S, Willard-Gallo K, Hatzis C, Szasz M, Kulka J, Larsimont D, Sotiriou C, Pusztai L, Desmedt C. Immune characterization of matched primary and multiple metastatic samples issued from an institutional autopsy cohort [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD5-10.
Collapse
Affiliation(s)
- B Szekely
- Semmelweis University, Budapest, Hungary; Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium; Sint Augustinus, Wilrijk, Belgium; Yale, New Haven
| | - Y Bareche
- Semmelweis University, Budapest, Hungary; Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium; Sint Augustinus, Wilrijk, Belgium; Yale, New Haven
| | - G Van den Eynden
- Semmelweis University, Budapest, Hungary; Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium; Sint Augustinus, Wilrijk, Belgium; Yale, New Haven
| | - R Salgado
- Semmelweis University, Budapest, Hungary; Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium; Sint Augustinus, Wilrijk, Belgium; Yale, New Haven
| | - L Buisseret
- Semmelweis University, Budapest, Hungary; Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium; Sint Augustinus, Wilrijk, Belgium; Yale, New Haven
| | - S Garaud
- Semmelweis University, Budapest, Hungary; Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium; Sint Augustinus, Wilrijk, Belgium; Yale, New Haven
| | - K Willard-Gallo
- Semmelweis University, Budapest, Hungary; Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium; Sint Augustinus, Wilrijk, Belgium; Yale, New Haven
| | - C Hatzis
- Semmelweis University, Budapest, Hungary; Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium; Sint Augustinus, Wilrijk, Belgium; Yale, New Haven
| | - M Szasz
- Semmelweis University, Budapest, Hungary; Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium; Sint Augustinus, Wilrijk, Belgium; Yale, New Haven
| | - J Kulka
- Semmelweis University, Budapest, Hungary; Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium; Sint Augustinus, Wilrijk, Belgium; Yale, New Haven
| | - D Larsimont
- Semmelweis University, Budapest, Hungary; Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium; Sint Augustinus, Wilrijk, Belgium; Yale, New Haven
| | - C Sotiriou
- Semmelweis University, Budapest, Hungary; Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium; Sint Augustinus, Wilrijk, Belgium; Yale, New Haven
| | - L Pusztai
- Semmelweis University, Budapest, Hungary; Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium; Sint Augustinus, Wilrijk, Belgium; Yale, New Haven
| | - C Desmedt
- Semmelweis University, Budapest, Hungary; Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium; Sint Augustinus, Wilrijk, Belgium; Yale, New Haven
| |
Collapse
|
7
|
Nguyen B, Marion M, Salgado R, Venet D, Vuylsteke P, Polastro L, Wieldiers H, Simon P, Lindeman G, Larsimont D, Van den Eynden G, Velghe C, Rothe F, Garaud S, Michiels S, Willard-Gallo K, Azim Jr HA, Loi S, Piccart M, Sotiriou C. Abstract PD5-06: The immunomodulatory potential of denosumab in breast cancer: results from D-BEYOND, a window of opportunity trial evaluating a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd5-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Breast cancer (BC) in young women has unique biology and poor prognosis. Previous reports suggest that they often express RANKL, which was also shown to play a role in mammary tumorigenesis and various immune processes. Here, we present the primary results of D-BEYOND, a window study investigating the biological activity of the RANKL inhibitor; denosumab in pre-menopausal BC patients.
Methods
D-BEYOND is a prospective, phase Iia, single-arm, multicenter study assessing the effect of denosumab on BC biology in premenopausal women with early BC (NCT01864798). Patients received two subcutaneous injections of denosumab (120mg), one week apart, followed by breast surgery. The primary endpoint was geometric mean change in tumor Ki67 assessed by immunohistochemistry (IHC). Blood, tumor and normal adjacent breast tissue were collected pre- and post-treatment. Serum levels of RANKL, OPG and CTX were assessed by ELISA. RNA was extracted from fresh-frozen tissue and RNAseq was performed. DESeq2 was used for differential expression analysis, GAGE was used for pathway analysis and CIBERSORT was used to infer immune cell subsets between pre- and post-treatment. Ki67, CD4/Foxp3 and CD4/CD8 IHC were performed on FFPE tissue to further assess the immune microenvironment. The percentage of TILs was independently evaluated by two pathologists on H&E slides. Pre- and post-treatment values were compared using a paired t-test.
Results
A total of 27 patients were enrolled in the study between October 2013 and July 2016. The median age was 45 years (range 35-51 years). Tumors of 21 patients were hormone receptor positive (77.8%), 4 were HER2 positive (14.8%) and 2 were triple negative (7.4%). No serious adverse events were reported, the most frequent non-serious adverse event being arthralgia (14.8%). After treatment, serum levels of CTX and RANKL decreased in all patients (P < 0.001) whereas OPG increased in 76.9% of patients (P = 0.009, 95% CI 0.56-0.91). There was no significant reduction of Ki67 values from baseline (geometric mean [GM] change after treatment; 0.98, 95% CI 0.76-1.26; P = 0.90). Twenty-four pre- and post-treatment tumor pairs were available for RNAseq, IHC and TILs evaluation. There was a significant increase in the percentage of stromal TILs after treatment (GM change of 1.75, 95% CI 1.28–2.39; P = 0.001). 1084 differentially expressed genes were identified and pathway analysis revealed enrichment of several immune processes. CIBERSORT revealed an enrichment of CD8+ T cells (GM change 1.72, 95% CI 1.19–2.48; P = 0.006) and a decrease of Treg cells (0.71, 95% CI 0.52–0.98, P = 0.040). These results were confirmed by IHC of CD8+ and CD4+/Foxp3+ cells (GM change 1.59, 95% CI 1.14–2.21; P = 0.008 and 0.63, 95% CI 0.49–0.83, P = 0.001, respectively).
Conclusion
Short course of denosumab did not reduce tumor proliferation rate. However, it induced a significant increase in TILs and CD8 cytotoxic T cells, while Treg infiltration decreased. These findings suggest an immunomodulatory role for denosumab in young breast cancer and that its use in combination could boost immunotherapy efficacy.
Citation Format: Nguyen B, Marion M, Salgado R, Venet D, Vuylsteke P, Polastro L, Wieldiers H, Simon P, Lindeman G, Larsimont D, Van den Eynden G, Velghe C, Rothe F, Garaud S, Michiels S, Willard-Gallo K, Azim Jr HA, Loi S, Piccart M, Sotiriou C. The immunomodulatory potential of denosumab in breast cancer: results from D-BEYOND, a window of opportunity trial evaluating a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD5-06.
Collapse
Affiliation(s)
- B Nguyen
- Institut Jules Bordet, ULB, Brussels, Belgium; CMSE, CHU UCL Namur, Namur, Belgium; UZ Leuven, KUL, Leven, Belgium; CHU Erasme, ULB, Brussels, Belgium; Peter MacCallum Cancer Centre, Melbourne, Australia; Institut Gustave Roussy, Paris, France; American University of Beirut (AUB), Beirut, Lebanon
| | - M Marion
- Institut Jules Bordet, ULB, Brussels, Belgium; CMSE, CHU UCL Namur, Namur, Belgium; UZ Leuven, KUL, Leven, Belgium; CHU Erasme, ULB, Brussels, Belgium; Peter MacCallum Cancer Centre, Melbourne, Australia; Institut Gustave Roussy, Paris, France; American University of Beirut (AUB), Beirut, Lebanon
| | - R Salgado
- Institut Jules Bordet, ULB, Brussels, Belgium; CMSE, CHU UCL Namur, Namur, Belgium; UZ Leuven, KUL, Leven, Belgium; CHU Erasme, ULB, Brussels, Belgium; Peter MacCallum Cancer Centre, Melbourne, Australia; Institut Gustave Roussy, Paris, France; American University of Beirut (AUB), Beirut, Lebanon
| | - D Venet
- Institut Jules Bordet, ULB, Brussels, Belgium; CMSE, CHU UCL Namur, Namur, Belgium; UZ Leuven, KUL, Leven, Belgium; CHU Erasme, ULB, Brussels, Belgium; Peter MacCallum Cancer Centre, Melbourne, Australia; Institut Gustave Roussy, Paris, France; American University of Beirut (AUB), Beirut, Lebanon
| | - P Vuylsteke
- Institut Jules Bordet, ULB, Brussels, Belgium; CMSE, CHU UCL Namur, Namur, Belgium; UZ Leuven, KUL, Leven, Belgium; CHU Erasme, ULB, Brussels, Belgium; Peter MacCallum Cancer Centre, Melbourne, Australia; Institut Gustave Roussy, Paris, France; American University of Beirut (AUB), Beirut, Lebanon
| | - L Polastro
- Institut Jules Bordet, ULB, Brussels, Belgium; CMSE, CHU UCL Namur, Namur, Belgium; UZ Leuven, KUL, Leven, Belgium; CHU Erasme, ULB, Brussels, Belgium; Peter MacCallum Cancer Centre, Melbourne, Australia; Institut Gustave Roussy, Paris, France; American University of Beirut (AUB), Beirut, Lebanon
| | - H Wieldiers
- Institut Jules Bordet, ULB, Brussels, Belgium; CMSE, CHU UCL Namur, Namur, Belgium; UZ Leuven, KUL, Leven, Belgium; CHU Erasme, ULB, Brussels, Belgium; Peter MacCallum Cancer Centre, Melbourne, Australia; Institut Gustave Roussy, Paris, France; American University of Beirut (AUB), Beirut, Lebanon
| | - P Simon
- Institut Jules Bordet, ULB, Brussels, Belgium; CMSE, CHU UCL Namur, Namur, Belgium; UZ Leuven, KUL, Leven, Belgium; CHU Erasme, ULB, Brussels, Belgium; Peter MacCallum Cancer Centre, Melbourne, Australia; Institut Gustave Roussy, Paris, France; American University of Beirut (AUB), Beirut, Lebanon
| | - G Lindeman
- Institut Jules Bordet, ULB, Brussels, Belgium; CMSE, CHU UCL Namur, Namur, Belgium; UZ Leuven, KUL, Leven, Belgium; CHU Erasme, ULB, Brussels, Belgium; Peter MacCallum Cancer Centre, Melbourne, Australia; Institut Gustave Roussy, Paris, France; American University of Beirut (AUB), Beirut, Lebanon
| | - D Larsimont
- Institut Jules Bordet, ULB, Brussels, Belgium; CMSE, CHU UCL Namur, Namur, Belgium; UZ Leuven, KUL, Leven, Belgium; CHU Erasme, ULB, Brussels, Belgium; Peter MacCallum Cancer Centre, Melbourne, Australia; Institut Gustave Roussy, Paris, France; American University of Beirut (AUB), Beirut, Lebanon
| | - G Van den Eynden
- Institut Jules Bordet, ULB, Brussels, Belgium; CMSE, CHU UCL Namur, Namur, Belgium; UZ Leuven, KUL, Leven, Belgium; CHU Erasme, ULB, Brussels, Belgium; Peter MacCallum Cancer Centre, Melbourne, Australia; Institut Gustave Roussy, Paris, France; American University of Beirut (AUB), Beirut, Lebanon
| | - C Velghe
- Institut Jules Bordet, ULB, Brussels, Belgium; CMSE, CHU UCL Namur, Namur, Belgium; UZ Leuven, KUL, Leven, Belgium; CHU Erasme, ULB, Brussels, Belgium; Peter MacCallum Cancer Centre, Melbourne, Australia; Institut Gustave Roussy, Paris, France; American University of Beirut (AUB), Beirut, Lebanon
| | - F Rothe
- Institut Jules Bordet, ULB, Brussels, Belgium; CMSE, CHU UCL Namur, Namur, Belgium; UZ Leuven, KUL, Leven, Belgium; CHU Erasme, ULB, Brussels, Belgium; Peter MacCallum Cancer Centre, Melbourne, Australia; Institut Gustave Roussy, Paris, France; American University of Beirut (AUB), Beirut, Lebanon
| | - S Garaud
- Institut Jules Bordet, ULB, Brussels, Belgium; CMSE, CHU UCL Namur, Namur, Belgium; UZ Leuven, KUL, Leven, Belgium; CHU Erasme, ULB, Brussels, Belgium; Peter MacCallum Cancer Centre, Melbourne, Australia; Institut Gustave Roussy, Paris, France; American University of Beirut (AUB), Beirut, Lebanon
| | - S Michiels
- Institut Jules Bordet, ULB, Brussels, Belgium; CMSE, CHU UCL Namur, Namur, Belgium; UZ Leuven, KUL, Leven, Belgium; CHU Erasme, ULB, Brussels, Belgium; Peter MacCallum Cancer Centre, Melbourne, Australia; Institut Gustave Roussy, Paris, France; American University of Beirut (AUB), Beirut, Lebanon
| | - K Willard-Gallo
- Institut Jules Bordet, ULB, Brussels, Belgium; CMSE, CHU UCL Namur, Namur, Belgium; UZ Leuven, KUL, Leven, Belgium; CHU Erasme, ULB, Brussels, Belgium; Peter MacCallum Cancer Centre, Melbourne, Australia; Institut Gustave Roussy, Paris, France; American University of Beirut (AUB), Beirut, Lebanon
| | - HA Azim Jr
- Institut Jules Bordet, ULB, Brussels, Belgium; CMSE, CHU UCL Namur, Namur, Belgium; UZ Leuven, KUL, Leven, Belgium; CHU Erasme, ULB, Brussels, Belgium; Peter MacCallum Cancer Centre, Melbourne, Australia; Institut Gustave Roussy, Paris, France; American University of Beirut (AUB), Beirut, Lebanon
| | - S Loi
- Institut Jules Bordet, ULB, Brussels, Belgium; CMSE, CHU UCL Namur, Namur, Belgium; UZ Leuven, KUL, Leven, Belgium; CHU Erasme, ULB, Brussels, Belgium; Peter MacCallum Cancer Centre, Melbourne, Australia; Institut Gustave Roussy, Paris, France; American University of Beirut (AUB), Beirut, Lebanon
| | - M Piccart
- Institut Jules Bordet, ULB, Brussels, Belgium; CMSE, CHU UCL Namur, Namur, Belgium; UZ Leuven, KUL, Leven, Belgium; CHU Erasme, ULB, Brussels, Belgium; Peter MacCallum Cancer Centre, Melbourne, Australia; Institut Gustave Roussy, Paris, France; American University of Beirut (AUB), Beirut, Lebanon
| | - C Sotiriou
- Institut Jules Bordet, ULB, Brussels, Belgium; CMSE, CHU UCL Namur, Namur, Belgium; UZ Leuven, KUL, Leven, Belgium; CHU Erasme, ULB, Brussels, Belgium; Peter MacCallum Cancer Centre, Melbourne, Australia; Institut Gustave Roussy, Paris, France; American University of Beirut (AUB), Beirut, Lebanon
| |
Collapse
|
8
|
Solinas C, de Wind A, Van den Eynden G, Ameye L, Garaud S, De Silva P, Boisson A, Noel G, Langouo Fontsa M, Buisseret L, de Azambuja E, Francis PA, Di Leo A, Crown JP, Sotiriou C, Larsimont D, Paesmans M, Piccart-Gebhart M, Willard-Gallo K. Abstract PD5-09: Immune parameters associated with survival in triple negative and HER2-positive breast cancer patients with 10 years of follow-up. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd5-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The clinical utility of tumor-infiltrating lymphocytes (TIL) is actively being investigated in breast cancer (BC). It is unclear whether TIL spatial location and organization in tertiary lymphoid structures (TLS) have an impact on prognosis. Additionally, the significance of PD-1 and PD-L1 expression is being debated due to conflicting data from several studies. We hypothesize that the presence, extent and spatial location of multiple immune biomarkers, reflecting ongoing immune responses, will be consistently associated with a good prognosis in highly infiltrated BC [triple-negative (TNBC) and HER2+].
The relationship between these immune biomarkers and clinical outcome was examined in the TNBC and HER2+ cohorts of node-positive BC patients enrolled in the BIG 02-98 adjuvant phase III trial with available material for immunohistochemical (IHC) labeling (N=113 and N=136, respectively). HER2+ patients did not receive trastuzumab. Dual IHC staining was performed on full-face consecutive tissue sections. Scoring was independently performed by two pathologists, blinded to the clinical data, and included: global, intratumoral and stromal TIL and TLS, assessed on CD3/CD20 slides; the percentage and location of PD-1 and PD-L1 expression, assessed on PD-1/PD-L1 slides. TIL were considered as a categorical variable with different cut-offs used for each parameter and for each cohort (TNBC and HER2+). Invasive disease-free survival (I-DFS) and overall survival (OS) were analyzed (median follow-up: 10 years). Cox proportional hazard models were used for survival analyses.
The TNBC cohort revealed an association between global TIL and outcome [adjusted hazard ratio (HR) for I-DFS: 0.27 (0.15-0.51); OS: 0.26 (0.13-0.53)]. Similar results were observed for stromal and intratumoral TIL. PD-L1 expression within TLS was an independent predictor of OS, after adjustment for tumor size and age [HR: 0.30 (0.09-0.99)]. Multivariate analysis reveals this effect was principally driven by high stromal TIL (>17.5% based on CD3/CD20 assessment) (χ2 OS: p=0.009). In contrast, no significant prognostic associations were found in the overall HER2+ cohort. However high T cell TIL were associated with improved I-DFS and OS in the ER-/HER2+ group [I-DFS: 0.34 (0.14-0.80); OS: 0.32 (0.12-0.86)] and stromal TIL were associated with improved I-DFS in the ER+/HER2+ group [HR: 0.29 (0.09-0.94)] (univariate analyses). No significant associations between the number of TLS nor the expression of PD-1 with outcomes were observed in either cohorts.
The presence of PD-L1+ TLS, driven by high baseline TIL, was associated with an excellent prognosis in node-positive TNBC. This observation might reflect specific immune activities taking place in these mini lymph node-like structures adjacent to the tumor bed where specific antitumor memory immune responses could be generated. No different prognostic impact was observed when analyzing TIL spatial location. Although the statistical power of the study might be limited, in line with previous findings our data reveal that, among the immune parameters evaluated, TIL are the strongest predictor of outcome in TNBC, while PD-L1+ TLS could be a new and important parameter that requires further investigation.
Citation Format: Solinas C, de Wind A, Van den Eynden G, Ameye L, Garaud S, De Silva P, Boisson A, Noel G, Langouo Fontsa M, Buisseret L, de Azambuja E, Francis PA, Di Leo A, Crown JP, Sotiriou C, Larsimont D, Paesmans M, Piccart-Gebhart M, Willard-Gallo K. Immune parameters associated with survival in triple negative and HER2-positive breast cancer patients with 10 years of follow-up [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD5-09.
Collapse
Affiliation(s)
- C Solinas
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - A de Wind
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - G Van den Eynden
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - L Ameye
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - S Garaud
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - P De Silva
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - A Boisson
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - G Noel
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - M Langouo Fontsa
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - L Buisseret
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - E de Azambuja
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - PA Francis
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - A Di Leo
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - JP Crown
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - C Sotiriou
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - D Larsimont
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - M Paesmans
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - M Piccart-Gebhart
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - K Willard-Gallo
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| |
Collapse
|
9
|
Solinas C, Richard F, Garaud S, De Silva P, de Wind A, Van Den Eyden G, Gu-Trantien C, Langouo Fontsa M, Noël G, Boisson A, Naveaux C, Duvillier H, Craciun L, Larsimont D, Willard-Gallo K. Unsupervised analysis of the extent, organization and phenotype of tumor-infiltrating lymphocytes in breast cancer identifies two major clusters. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy493.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Buisseret L, Pommey S, Allard B, Garaud S, Bergeron MA, Cousineau I, Ameye L, Paesmans M, Crown JPA, Di Leo A, Piccart-Gebhart M, Willard-Gallo K, Sotiriou C, Stagg J. Abstract PD6-07: Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd6-07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: CD73 is an ecto-enzyme that promotes tumor immune escape through the production of immunosuppressive extracellular adenosine in the tumor microenvironment. Several CD73 inhibitors and adenosine receptor antagonists are being evaluated in phase I clinical trials.
Objective: To investigate the prognosis significance of CD73 in human triple-negative breast cancer.
Design and setting: This is a prospective-retrospective biomarker analysis. Using multiplex immunofluorescence and image analysis, we assessed CD73 protein expression on tumor cells, tumor-infiltrating leukocytes and stromal cells on full-face sections from formalin-fixed paraffin-embedded primary breast tumors.
Participants: 122 samples of triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial were included in our analysis. This trial compared the addition of taxanes to anthracyclines-based chemotherapy in node-positive breast cancer.
Results: Our results demonstrated that high levels of CD73 expression on epithelial tumor cells were significantly associated with reduced disease-free survival (DFS) and overall survival (OS) in patients with triple-negative breast cancer. Using the median as a threshold between low and high levels of CD73 on epithelial cells, hazard ratios (HR) adjusted for grade, number of positive lymph nodes and tumor size, were of 2.21 (95% confidence interval (CI): 1.15-4.25); p=0.02 for DFS and of 2.47 (95%CI: 1.21-5.07); p=0.01 for OS. CD73 expression negatively correlated with tumor immune infiltration (Spearman's R= -0.50, p<0.0001). Patients with high levels of CD73 and low levels of tumor-infiltrating leukocytes had the worse clinical outcome (HR: 4.24 (1.90-9.45), p<0.001 for DFS, HR: 3.91 (1.65-9.31), p=0.002 for OS) compared to patients with low CD73 and high tumor-immune infiltration. Flow cytometric analysis of tumor-infiltrating leukocytes revealed a high frequency of CD73-expressing B cells and higher CD73 expression on tumor-infiltrating myeloid cells and natural killer cells compared to peripheral blood.
Conclusion and relevance: Taken together, our study provides further support that CD73 expression is associated with a poor prognosis and reduced anti-tumor immunity in human triple-negative breast cancer and that targeting CD73 could be a promising strategy to reprogram the tumor microenvironment in this breast cancer subtype.
Citation Format: Buisseret L, Pommey S, Allard B, Garaud S, Bergeron MA, Cousineau I, Ameye L, Paesmans M, Crown JPA, Di Leo A, Piccart-Gebhart M, Willard-Gallo K, Sotiriou C, Stagg J. Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD6-07.
Collapse
Affiliation(s)
- L Buisseret
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada; Institut Jules Bordet- Université Libre de Bruxelles, Belgium; Irish Clinical Oncology Research Group, Dublin, Ireland; Hospital of Prato, Prato, Italy
| | - S Pommey
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada; Institut Jules Bordet- Université Libre de Bruxelles, Belgium; Irish Clinical Oncology Research Group, Dublin, Ireland; Hospital of Prato, Prato, Italy
| | - B Allard
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada; Institut Jules Bordet- Université Libre de Bruxelles, Belgium; Irish Clinical Oncology Research Group, Dublin, Ireland; Hospital of Prato, Prato, Italy
| | - S Garaud
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada; Institut Jules Bordet- Université Libre de Bruxelles, Belgium; Irish Clinical Oncology Research Group, Dublin, Ireland; Hospital of Prato, Prato, Italy
| | - MA Bergeron
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada; Institut Jules Bordet- Université Libre de Bruxelles, Belgium; Irish Clinical Oncology Research Group, Dublin, Ireland; Hospital of Prato, Prato, Italy
| | - I Cousineau
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada; Institut Jules Bordet- Université Libre de Bruxelles, Belgium; Irish Clinical Oncology Research Group, Dublin, Ireland; Hospital of Prato, Prato, Italy
| | - L Ameye
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada; Institut Jules Bordet- Université Libre de Bruxelles, Belgium; Irish Clinical Oncology Research Group, Dublin, Ireland; Hospital of Prato, Prato, Italy
| | - M Paesmans
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada; Institut Jules Bordet- Université Libre de Bruxelles, Belgium; Irish Clinical Oncology Research Group, Dublin, Ireland; Hospital of Prato, Prato, Italy
| | - JPA Crown
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada; Institut Jules Bordet- Université Libre de Bruxelles, Belgium; Irish Clinical Oncology Research Group, Dublin, Ireland; Hospital of Prato, Prato, Italy
| | - A Di Leo
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada; Institut Jules Bordet- Université Libre de Bruxelles, Belgium; Irish Clinical Oncology Research Group, Dublin, Ireland; Hospital of Prato, Prato, Italy
| | - M Piccart-Gebhart
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada; Institut Jules Bordet- Université Libre de Bruxelles, Belgium; Irish Clinical Oncology Research Group, Dublin, Ireland; Hospital of Prato, Prato, Italy
| | - K Willard-Gallo
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada; Institut Jules Bordet- Université Libre de Bruxelles, Belgium; Irish Clinical Oncology Research Group, Dublin, Ireland; Hospital of Prato, Prato, Italy
| | - C Sotiriou
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada; Institut Jules Bordet- Université Libre de Bruxelles, Belgium; Irish Clinical Oncology Research Group, Dublin, Ireland; Hospital of Prato, Prato, Italy
| | - J Stagg
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada; Institut Jules Bordet- Université Libre de Bruxelles, Belgium; Irish Clinical Oncology Research Group, Dublin, Ireland; Hospital of Prato, Prato, Italy
| |
Collapse
|
11
|
Allard B, Aspeslagh S, Garaud S, Dupont FA, Solinas C, Kok M, Routy B, Sotiriou C, Stagg J, Buisseret L. Immuno-oncology-101: overview of major concepts and translational perspectives. Semin Cancer Biol 2018; 52:1-11. [PMID: 29428479 DOI: 10.1016/j.semcancer.2018.02.005] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2018] [Accepted: 02/05/2018] [Indexed: 02/06/2023]
Abstract
Cancer immunotherapy is demonstrating impressive clinical benefit in different malignancies and clinical oncologists are increasingly turning their attention to immune-oncology. It is now well recognized that innate and adaptive immune cells infiltrating tumors are associated with clinical outcomes and responses to treatments, and can be harnessed to patients' benefit. Considerable advances have also been made in understanding how cancers escape from immune attack. Targeting of immunological escape processes regulated by the expression of immune checkpoint receptors and ligands and the down-modulation of tumor antigen presentation is the basis of immuno-oncology treatments. Despite recent achievements, there remain a number of unresolved issues in order to successfully implement cancer immunotherapy in many cancers. Importantly, clinical biomarkers are still needed for better optimization of emerging combination immunotherapies and better treatment tailoring. In this review, we summarize the function of innate and adaptive immune cells in anti-tumor immunity and the general mechanisms exploited by tumor cells to escape and inhibit immune responses as well as therapeutic strategies developed to overcome these mechanisms and discuss emerging biomarkers in immuno-oncology.
Collapse
Affiliation(s)
- B Allard
- University of Montreal Hospital Research Centre, Montréal, Québec, Canada; Montreal Cancer Institute, Montreal, Quebec, Canada; Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada
| | - S Aspeslagh
- Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - S Garaud
- Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - F A Dupont
- Breast Cancer Translational Research Laboratory J-C Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - C Solinas
- Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - M Kok
- Department of Medical Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - B Routy
- University of Montreal Hospital Research Centre, Montréal, Québec, Canada; Montreal Cancer Institute, Montreal, Quebec, Canada
| | - C Sotiriou
- Breast Cancer Translational Research Laboratory J-C Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - J Stagg
- University of Montreal Hospital Research Centre, Montréal, Québec, Canada; Montreal Cancer Institute, Montreal, Quebec, Canada; Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada
| | - L Buisseret
- Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory J-C Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
| |
Collapse
|
12
|
Craciun L, De Wind R, Demetter P, Lucidi V, Michiels S, Garaud S, Naveaux C, Gomez Galdon M, Hendlisz A, Willard Gallo K, Flamen P, Larsimont D, Donckier V. Selective internal radiation therapy (SIRT) promotes the recruitment of tumor-infiltrating lymphocytes and enhances cytotoxic activity in hepatocellular carcinoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx710.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S, Fumagalli D, de Azambuja E, Salgado R, Sotiriou C, Willard-Gallo K, Ignatiadis M. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. Cancer Treat Rev 2017; 57:8-15. [DOI: 10.1016/j.ctrv.2017.04.005] [Citation(s) in RCA: 56] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2017] [Revised: 04/21/2017] [Accepted: 04/23/2017] [Indexed: 01/13/2023]
|
14
|
Buisseret L, Pommey S, Allard B, Garaud S, Ameye L, Di Leo A, Crown J, Piccart-Gebhart M, Sotiriou C, Stagg J. Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx138.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Solinas C, Ceppi M, Lambertini M, Scartozzi M, Garaud S, Fumagalli D, De Azambuja E, Salgado R, Willard-Gallo K, Ignatiadis M. Tumor infiltrating lymphocytes in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of published randomized clinical trials. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx138.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Willard-Gallo K, Solinas C, Marcoux D, t'Kint de Roodenbeke D, Garaud S, Van den Eynden G, de Wind A, Boisson A, Larsimont D, Piccart M. Abstract P2-04-04: BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-04-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The remarkable responses observed in metastatic cancer patients treated with immunotherapies, including inhibitors directed to the PD-1 and PD-L1 checkpoint molecules, makes it a priority to identify critical variations in pro- and anti-tumor immune responses in breast cancer (BC). In patients with triple negative (TN) BC, an increased presence of tumor infiltrating lymphocytes (TIL) and tertiary lymphoid structures (TLS) have been associated with good clinical outcomes. However, the frequency of specific lymphocyte subpopulations, PD-1 and/or PD-L1 expression and their prognostic significance remains an open question. Our recent work found that PD-1 and PD-L1 expression are specifically associated with higher TIL densities and an increased number of TLS in BC. We further demonstrated that TIL density, TLS and PD-L1 expression were correlated with more aggressive breast tumor characteristics, including higher proliferation and hormone receptor negativity. In this project, we examined the prevalence of TIL, TLS, PD-1 and PD-L1 expression in TNBC and further compared these immune parameters between TNBC patients harboring BRCA1 or BRCA2 germline gene mutations with those carrying the wild-type (wt) genes.
A total of 1402 BC patients whose blood was genetically tested for germline BRCA1 and BRCA2 mutations were examined for inclusion in this study. Ninety-eight chemotherapy-naïve patients with primary invasive ER–, PR– and HER2– BC and demonstrated germline BRCA1 or BRCA2 wt or mutated-gene status were included in this study. Ninety-four tumors were determined to be suitable for evaluating immune cell infiltration (51 BRCA wt and 43 BRCA-mutated). FFPE tumor tissue from the surgical specimens was analyzed by immunohistochemistry (IHC) staining of full-face tissue sections. IHC was performed as a dual label using CD3 plus CD20 for T and B cells, CD4 plus CD8 for the major T cell subpopulations and PD-1 plus PD-L1 for individual or paired expression of these receptors. The stained slides were independently scored by two experienced pathologists for TIL, TIL subpopulations, TLS and checkpoint molecule expression.
These analyses revealed that 87% of our TNBC cohort was TIL-positive (≥10% TIL) with 35% classified as lymphocyte predominant BC (LPBC; ≥50% TIL). T cells were the principal component of the lymphocytic infiltrate with no significant differences between the BRCA wt and BRCA-mutated groups detected in total T cells (CD3+), helper T cells (CD4+), cytotoxic T cells (CD8+) or B cells (CD20+). TLS were identified in 73% of tumors with again no significant differences between the BRCA groups. Examination of checkpoint molecule expression identified 33% tumors as PD-1 positive and 40% as PD-L1 positive. PD-1 expression was correlated with PD-L1 expression and both with TIL positivity and the level of immune infiltration but not BRCA mutational status.
Overall, our analyses revealed that BRCA wt and BRCA-mutated TNBC are remarkably similar in terms of TIL heterogeneity, a TLS presence and checkpoint molecule expression. These data suggest that BRCA gene mutations are not immunogenic nor do they directly drive immune infiltration in TNBC.
Citation Format: Willard-Gallo K, Solinas C, Marcoux D, t'Kint de Roodenbeke D, Garaud S, Van den Eynden G, de Wind A, Boisson A, Larsimont D, Piccart M. BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-04-04.
Collapse
Affiliation(s)
- K Willard-Gallo
- Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; GZA Ziekenhuizen, Wilrijk, Belgium
| | - C Solinas
- Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; GZA Ziekenhuizen, Wilrijk, Belgium
| | - D Marcoux
- Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; GZA Ziekenhuizen, Wilrijk, Belgium
| | - D t'Kint de Roodenbeke
- Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; GZA Ziekenhuizen, Wilrijk, Belgium
| | - S Garaud
- Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; GZA Ziekenhuizen, Wilrijk, Belgium
| | - G Van den Eynden
- Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; GZA Ziekenhuizen, Wilrijk, Belgium
| | - A de Wind
- Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; GZA Ziekenhuizen, Wilrijk, Belgium
| | - A Boisson
- Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; GZA Ziekenhuizen, Wilrijk, Belgium
| | - D Larsimont
- Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; GZA Ziekenhuizen, Wilrijk, Belgium
| | - M Piccart
- Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; GZA Ziekenhuizen, Wilrijk, Belgium
| |
Collapse
|
17
|
Verdonck M, Denayer A, Delvaux B, Garaud S, De Wind R, Desmedt C, Sotiriou C, Willard-Gallo K, Goormaghtigh E. Characterization of human breast cancer tissues by infrared imaging. Analyst 2017; 141:606-19. [PMID: 26535413 DOI: 10.1039/c5an01512j] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Fourier Transform InfraRed (FTIR) spectroscopy coupled to microscopy (IR imaging) has shown unique advantages in detecting morphological and molecular pathologic alterations in biological tissues. The aim of this study was to evaluate the potential of IR imaging as a diagnostic tool to identify characteristics of breast epithelial cells and the stroma. In this study a total of 19 breast tissue samples were obtained from 13 patients. For 6 of the patients, we also obtained Non-Adjacent Non-Tumor tissue samples. Infrared images were recorded on the main cell/tissue types identified in all breast tissue samples. Unsupervised Principal Component Analyses and supervised Partial Least Square Discriminant Analyses (PLS-DA) were used to discriminate spectra. Leave-one-out cross-validation was used to evaluate the performance of PLS-DA models. Our results show that IR imaging coupled with PLS-DA can efficiently identify the main cell types present in FFPE breast tissue sections, i.e. epithelial cells, lymphocytes, connective tissue, vascular tissue and erythrocytes. A second PLS-DA model could distinguish normal and tumor breast epithelial cells in the breast tissue sections. A patient-specific model reached particularly high sensitivity, specificity and MCC rates. Finally, we showed that the stroma located close or at distance from the tumor exhibits distinct spectral characteristics. In conclusion FTIR imaging combined with computational algorithms could be an accurate, rapid and objective tool to identify/quantify breast epithelial cells and differentiate tumor from normal breast tissue as well as normal from tumor-associated stroma, paving the way to the establishment of a potential complementary tool to ensure safe tumor margins.
Collapse
Affiliation(s)
- M Verdonck
- Laboratory of Structure and Function of Biological Membranes, Center of Structural Biology and Bioinformatics, Université Libre de Bruxelles, Brussels, Belgium.
| | - A Denayer
- Laboratory of Structure and Function of Biological Membranes, Center of Structural Biology and Bioinformatics, Université Libre de Bruxelles, Brussels, Belgium.
| | - B Delvaux
- Laboratory of Structure and Function of Biological Membranes, Center of Structural Biology and Bioinformatics, Université Libre de Bruxelles, Brussels, Belgium.
| | - S Garaud
- Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - R De Wind
- Pathological Anatomy Department, Institut Jules Bordet, Brussels, Belgium
| | - C Desmedt
- Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Brussels, Belgium
| | - C Sotiriou
- Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Brussels, Belgium
| | - K Willard-Gallo
- Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - E Goormaghtigh
- Laboratory of Structure and Function of Biological Membranes, Center of Structural Biology and Bioinformatics, Université Libre de Bruxelles, Brussels, Belgium.
| |
Collapse
|
18
|
Solinas C, Boisson A, Brown D, de Wind R, van den Eynden G, Garaud S, Buisseret L, Naveaux C, Sotiriou C, Larsimont D, Piccart M, Willard-Gallo K. Tumor infiltrating lymphocytes and tertiary lymphoid structures in paired primary tumors and metastases from breast cancer patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw393.07] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Desmedt C, Salgado R, Buisseret L, Zoppoli G, Fornili M, Van den Eynden G, Garaud S, Gundem G, Rothé F, Brown D, Kheddoumi N, Rouas G, Galant C, Bertucci F, Piccart M, Campbell P, Viale G, Larsimont D, Willard-Gallo K, Biganzoli E, Pruneri G, Sotiriou C. Abstract S1-02: Lymphocytic infiltration in invasive lobular breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-s1-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The presence and prognostic value of tumor infiltrating lymphocytes (TILs) in invasive breast carcinoma has been demonstrated in several studies, especially in the triple-negative and HER2-positive subtypes. So far, TILs have not been investigated with sufficient detail in invasive lobular breast cancer (ILBC). Here we therefore aimed at: first, assessing the distribution of stromal TILs in ILBC; second, correlating the presence of TILs with standard clinical and pathological markers; third, exploring associations of TILs with recurrent genomic alterations; and, fourth, comparing the lymphocytic composition of ER-positive/HER2-negative lobular to ER-positive/HER2-negative ductal tumors.
Material and methods: The percentage of stromal TILs was independently assessed according to Salgado et al. (Ann Oncol 2015) by three pathologists on full-face hematoxylin and eosin slides in a well-annotated retrospective series of 614 primary ILBCs previously characterized at the genomic level. The median value of TILs was used for the analyses. For the association analyses, we focused on the more homogeneous group of ER-positive/HER2-negative ILBC (555/614). Breast cancer-free interval was used as survival endpoint and the analyses were censored at 12 years of follow-up. The comparison of the lymphocytic composition (relative percentage of CD45+ TILs which are CD4+, CD8+ or CD19+) was assessed by FACS in a separate prospective cohort of 51 ER-positive/HER2-negative lobular and 112 ER-positive/HER2-negative ductal tumors.
Results: The intraclass correlation coefficient between the three pathologists was 0.71 (95%CI:0.65-0.76). The median percentage of stromal TILs was 5% and the interquartile range 5-10%, with only 9% of the samples having ≥ 20%. Greater numbers of TILs were significantly associated with younger age at diagnosis, axillary lymph node involvement, high proliferative tumors as assessed by Ki67, and with the mixed non-classic ILBC subtypes. Greater numbers of TILs were associated with worse prognosis (HR=1.22; 95%CI:1.07-1.38, p=0.003) only in the unadjusted analysis, as it lost significance after adjustment for standard clinical and pathological variables. Greater numbers of TILs were observed in tumors harboring ARID1A, BRCA2, KMT2C and TP53 mutations, as well as chr3p21.31 and chr8q24.23 (PTK2) loss; whereas lower numbers were observed in tumors with ERBB3 mutations as well as chr7p and chr11q14.1 (PAK1) gains. There were no significant differences in the relative proportion of CD4+, CD8+ or CD19+ lymphocytes between ER-positive/HER2-negative lobular and ductal tumors.
Conclusion: In this work, which reports to our knowledge on the largest series of ILBC ever assessed for TILs, we showed that most ILBCs were characterized by low lymphocytic infiltration. Besides the association of TILs with clinical and pathological features of ILBC patients, we found that higher TIL levels were observed in the presence of specific mutations and copy number alterations. Higher numbers of TILs were associated with worse prognosis at the univariate analysis. Finally, based on the assessed markers, we have no evidence of differential lymphocytic composition between ER-positive/HER2-negative lobular and ductal tumors.
Citation Format: Desmedt C, Salgado R, Buisseret L, Zoppoli G, Fornili M, Van den Eynden G, Garaud S, Gundem G, Rothé F, Brown D, Kheddoumi N, Rouas G, Galant C, Bertucci F, Piccart M, Campbell P, Viale G, Larsimont D, Willard-Gallo K, Biganzoli E, Pruneri G, Sotiriou C. Lymphocytic infiltration in invasive lobular breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr S1-02.
Collapse
Affiliation(s)
- C Desmedt
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| | - R Salgado
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| | - L Buisseret
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| | - G Zoppoli
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| | - M Fornili
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| | - G Van den Eynden
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| | - S Garaud
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| | - G Gundem
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| | - F Rothé
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| | - D Brown
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| | - N Kheddoumi
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| | - G Rouas
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| | - C Galant
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| | - F Bertucci
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| | - M Piccart
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| | - P Campbell
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| | - G Viale
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| | - D Larsimont
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| | - K Willard-Gallo
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| | - E Biganzoli
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| | - G Pruneri
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| | - C Sotiriou
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy
| |
Collapse
|
20
|
Solinas C, Buisseret L, Garaud S, Boisson A, Naveaux C, de Wind R, Van den Eynden G, Brown D, Larsimont D, Sotiriou C, Willard-Gallo K. PDL1 and PD1 expression by tumor infiltrating lymphocytes in primary breast cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv336.04] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Verdonck M, Garaud S, Duvillier H, Willard-Gallo K, Goormaghtigh E. Label-free phenotyping of peripheral blood lymphocytes by infrared imaging. Analyst 2015; 140:2247-56. [PMID: 25516910 DOI: 10.1039/c4an01855a] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
It is now widely accepted that the immune microenvironment of tumors and more precisely Tumor Infiltrating Lymphocytes (TIL) play an important role in cancer development and outcome. TILs are considered to be important prognostic and predictive factors based on a growing body of clinical evidence; however, their presence at the tumor site is not currently assessed routinely. FTIR (Fourier transform infrared) imaging has proven it has value in studying a range of tumors, particularly for characterizing tumor cells. Currently, very little is known about the potential for FTIR imaging to characterize TIL. The present proof of concept study investigates the ability of FTIR imaging to identify the principal lymphocyte subpopulations present in human peripheral blood (PB). A negative cell isolation method was employed to select pure, label-free, helper T cells (CD4(+)), cytotoxic T cells (CD8(+)) and B cells (CD19(+)) from six healthy donors PB by Fluorescence Activated Cell Sorting (FACS). Cells were centrifuged onto Barium Fluoride windows and ten infrared images were recorded for each lymphocyte subpopulation from all six donors. After spectral pre-treatment, statistical analyses were performed. Unsupervised Principal Component Analyses (PCA) revealed that in the absence of donor variability, CD4(+) T cells, CD8(+) T cells and B cells each display distinct IR spectral features. Supervised Partial Least Square Discriminant Analyses (PLS-DA) demonstrated that the differences between the three lymphocyte subpopulations are reflected in their IR spectra, permitting their individual identification even when significant donor variability is present. Our results also show that a distinct spectral signature is associated with antibody binding. To our knowledge this is the first study reporting that FTIR imaging can effectively identify T and B lymphocytes and differentiate helper T cells from cytotoxic T cells. This proof of concept study demonstrates that FTIR imaging is a reliable tool for the identification of lymphocyte subpopulations and has the potential for use in characterizing TIL.
Collapse
Affiliation(s)
- M Verdonck
- Laboratory for the Structure and Function of Biological Membranes, Center for Structural Biology and Bioinformatics, Université Libre de Bruxelles, Campus Plaine, Bd du Triomphe 2, CP206/02, B1050 Brussels, Belgium.
| | | | | | | | | |
Collapse
|
22
|
Solinas C, Buisseret L, Garaud S, Boisson A, Naveaux C, De Silva P, Migliori E, de Wind R, Larsimont D, Willard-Gallo K. Evaluation of PDL1 expression in breast cancer by immunohistochemistry. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv118.04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Verdonck M, Garaud S, de Wind R, Willard-Gallo K, Goormaghtigh E. Infrared imaging: A potential new tool to probe tumor cells and their immune micro-environment in breast cancer? Ann Oncol 2015. [DOI: 10.1093/annonc/mdv117.36] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
24
|
Migliori E, Gu-Trantien C, Garaud S, Buisseret L, Duvillier H, Lodewyckx JN, Van Schoonwinkel L, Boisson A, Willard-Gallo K. CXCL13 and tertiary lymphoid structures formation in the anti-breast cancer immune response. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv118.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
De Silva P, Garaud S, Migliori E, Solinas C, Boisson A, Naveaux C, Pecenko S, de Wind R, Larsimont D, Willard-Gallo K. Expression of transcription factor FOXP1 in the immune response to breast cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv118.05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
26
|
Buisseret L, Garaud S, Duvillier H, Naveaux C, Duquenne S, de Wind A, Vakili J, Sotiriou C, Willard-Gallo K. Lymphocytes Infiltrating Breast Cancer : Density, Composition and Organization. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu067.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Garaud S, Buisseret L, Gu-Trantien C, Lodewyckx J, Duvillier H, Craciun L, Larsimont D, Willard-Gallo K. Characterization of B Cells Infiltrating Human Breast Cancer. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu067.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Verdonck M, Garaud S, Buisseret L, Duvillier H, Desmedt C, de Wind R, Sotiriou C, Willard-Gallo K, Goormaghtigh E. Characterization of Tumor Infiltrating Lymphocytes in Human Breast Cancer by Infrared Imaging. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu068.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
29
|
Willard-Gallo K, Garaud S, Buisseret L, Gu-Trantien C, Migliori E, Lodewyckx JN, Naveaux C, de Wind A, Duquenne S, Larsimont D, Sotiriou C, Piccart M. Abstract P5-01-02: Characterization of follicular helper CD4 T cells and B cells resident in peritumoral tertiary lymphocyte structures as specific markers for an immunological grade in breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p5-01-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Molecular approaches such as gene expression profiling have improved the classification of human breast cancer (BC) by identifying molecular subtypes and demonstrating that the immune infiltrate is an important prognostic or predictive factor. Our prospective study of freshly isolated CD4+ T cells infiltrating (TIL) BC discovered that along with Th1, Th2 and Th17 effector memory and Treg subpopulations the newest CD4+ Th subset, T follicular helper (Tfh) cells, was also present in the tumor. Comparison of extensive versus minimally-infiltrated tumors led to our finding that extensive immune infiltrates are distinguished by Tfh cells located in tertiary lymphoid structures (TLS) next to the tumor bed. TLS are highly organized with a CD3+ T cell zone adjacent to a CD20+ B cell follicle with germinal centers containing Bcl6+ Tfh cells, CD23+ follicular dendritic cells and Ki67+ cells. Tfh cells are known to play a critical role in generating antibody producing plasma cells and memory B cells. We demonstrated that Tfh cells are the principal cellular source of the B cell chemoattractant CXCL13 in BC. Thus, a Tfh presence paralleled the TLS incidence and together they were associated with an increased peritumoral B cell presence and a higher frequency of CD8+ T cells in the tumor bed. Our recent work shows that approximately 50% of the infiltrating B cells are memory cells in contrast to normal and non-tumor non-adjacent breast tissue (controls, less than 15%). A significant B cell presence is found in extensively infiltrated high proliferative BC subtypes with germinal center centroblasts and centrocytes consistently associated with a Tfh cell presence. We assessed immunoglobulin isotypes in supernatants of fresh breast tissue homogenates, detecting decreased IgA and increased IgG and IgM in the tumor tissue compared to controls. Patient sera, particularly from patients with high proliferative BC subtypes, had elevated IgG3 and IgG4 compared to low proliferative tumors and healthy donors. Immunofluorescent analysis found the majority of B cells infiltrating tumors have germinal center characteristics (IgD+Ki67+CD35+CD21+PD-1+) and are clustered with Tfh in the B cell follicles surrounded by a T cell zone, which together create the tumor-associated TLS. Based on their specificity for TLS, we derived a scoring system, referred to as immunological grade, to measure the extent of the lymphocytic infiltrate and the level of immune organization. This system is based on a morphological score (the density of the lymphocyte infiltrate determined by CD3/CD20 immunohistochemistry plus the number and size of peritumoral TLS assessed by two pathologists) together with a molecular score [an 8 gene qRT-PCR Tfh signature that predicts long term survival in an untreated patient cohort with >10-year survival (n = 794) or pathological complete response in patients treated with preoperative chemotherapy (n = 996)]. We are testing this immunological grading system on a large retrospective series of patients to determine its value in evaluating a patient's anti-tumor immune response in pre-operative biopsies and/or the primary tumor at surgery as a new marker for use in treatment decisions.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-01-02.
Collapse
Affiliation(s)
- K Willard-Gallo
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - S Garaud
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - L Buisseret
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - C Gu-Trantien
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - E Migliori
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - J-N Lodewyckx
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - C Naveaux
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - A de Wind
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - S Duquenne
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - D Larsimont
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - C Sotiriou
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - M Piccart
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| |
Collapse
|
30
|
Buisseret L, Garaud S, Duvillier H, Craciun L, Naveaux C, Lodewyckx J, Larsimont D, Sotiriou C, Willard-Gallo K. The Composition and Organization of Lymphocytes Infiltrating Human Breast Cancer. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt085.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Verdonck M, Garaud S, Duvillier H, Vermeulen N, Buisseret L, Desmedt C, de Wind R, Sotiriou C, Willard-Gallo K, Goormaghtigh E. Infrared Imaging: a Potential New Tool to Characterize Lymphocytic Infiltration in Human Breast Cancer. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt144.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
32
|
Renaudineau Y, Garaud S, Pers JO, Youinou P. NFAT2 and STAT3 control type 2 cytokines in CD5 B cells. Ann Rheum Dis 2010. [DOI: 10.1136/ard.2010.129585h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|